Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2958)	6/23/2010 1:55:57 PM
From: Jibacoa	1 Recommendation Read Replies (1) of 3722

ARWR continues to hold above the support at the $2.20 level.<g> bigcharts.marketwatch.com It announced today the closing of its recent $8.6M offering. Its CEO,Christopher Anzalone,said that he expects that the subsidiaries, Calando and Unidym will now be on a better position to maximize their values and approach potential partnerships from "a position of strength". <g> Calando has already demonstrated that its systemic siRNA delivery and gene silencing in humans works as expected, Unidym has made great progress in the touch panel markets. As mentioned, the ACTAY is $9 But although ARWR has room to run, I will still keep a target at $3.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next